​
​

TC Biopharm Ownership 2024 | Who Owns TC Biopharm Now?

OverviewFinancialsChart

Institutional Ownership

0.22%

Insider Ownership

0.02%

Retail Ownership

99.76%

Institutional Holders

5.00

TC Biopharm Institutional Shareholders

Institutional Shareholders by % of Total Shares

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
ARMISTICE CAPITAL, LLC21.87%0.00%120,68437,97245.91%193,094,000Mar 31, 2023
WELLS FARGO & COMPANY/MN1.27%-7,0007,000100.00%11,200,000Mar 31, 2023
STEWARD FINANCIAL GROUP LLC0.36%0.00%2,0002,000100.00%3,000Mar 31, 2023
MORGAN STANLEY0.00%-2020100.00%32,000Mar 31, 2023
UBS GROUP AG----1,392-100.00%-Mar 31, 2023

TC Biopharm's largest institutional shareholder is ARMISTICE CAPITAL, LLC, holding 21.87% of the company's total share outstanding, currently valued at $193.09M. The top 10 institutional shareholders own together 23.50% of the company.

Institutional Shareholders by % of Total Assets

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
ARMISTICE CAPITAL, LLC21.87%0.00%120,68437,97245.91%193,094,000Mar 31, 2023
STEWARD FINANCIAL GROUP LLC0.36%0.00%2,0002,000100.00%3,000Mar 31, 2023
WELLS FARGO & COMPANY/MN1.27%-7,0007,000100.00%11,200,000Mar 31, 2023
MORGAN STANLEY0.00%-2020100.00%32,000Mar 31, 2023
UBS GROUP AG----1,392-100.00%-Mar 31, 2023

The largest TC Biopharm shareholder by % of total assets is ARMISTICE CAPITAL, LLC. The company owns 120.68K shares of TC Biopharm (TCBP), representing 0.00% of its total assets.

Institutional Buyers

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
ARMISTICE CAPITAL, LLC21.87%0.00%120,68437,97245.91%193,094,000Mar 31, 2023
WELLS FARGO & COMPANY/MN1.27%-7,0007,000100.00%11,200,000Mar 31, 2023
STEWARD FINANCIAL GROUP LLC0.36%0.00%2,0002,000100.00%3,000Mar 31, 2023
MORGAN STANLEY0.00%-2020100.00%32,000Mar 31, 2023
UBS GROUP AG----1,392-100.00%-Mar 31, 2023

As of Mar 31 2023, TC Biopharm's largest institutional buyer is ARMISTICE CAPITAL, LLC. The company purchased 37.97K stocks of TCBP, valued at $193.09M.

Institutional Sellers

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
UBS GROUP AG----1,392-100.00%-Mar 31, 2023
MORGAN STANLEY0.00%-2020100.00%32,000Mar 31, 2023
STEWARD FINANCIAL GROUP LLC0.36%0.00%2,0002,000100.00%3,000Mar 31, 2023
WELLS FARGO & COMPANY/MN1.27%-7,0007,000100.00%11,200,000Mar 31, 2023
ARMISTICE CAPITAL, LLC21.87%0.00%120,68437,97245.91%193,094,000Mar 31, 2023

As of Mar 31 2023, TC Biopharm's biggest institutional seller is UBS GROUP AG. The company sold -1.39K shares of TCBP, valued at -.

Institutional New positions

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
WELLS FARGO & COMPANY/MN1.27%-7,0007,000100.00%11,200,000Mar 31, 2023
STEWARD FINANCIAL GROUP LLC0.36%0.00%2,0002,000100.00%3,000Mar 31, 2023
MORGAN STANLEY0.00%-2020100.00%32,000Mar 31, 2023

TC Biopharm's largest new institutional shareholder by number of shares is WELLS FARGO & COMPANY/MN, purchased 7.00K shares, valued at $11.20M, as of undefined.

Institutional Sold Out

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
UBS GROUP AG----1,392-100.00%-Mar 31, 2023

TC Biopharm's largest sold out institutional shareholder by shares sold is UBS GROUP AG, sold -1.39K shares, valued at -, as of undefined.

TC Biopharm Mutual Fund Holders

Name% Total AssetsTotal SharesChange AmountChange %Date
TRUST FOR PROFESSIONAL MANAGERS0.00%19,068--Feb 29, 2024

TC Biopharm's largest mutual fund holder by % of total assets is "TRUST FOR PROFESSIONAL MANAGERS", owning 19.07K shares, compromising 0.00% of its total assets.

TC Biopharm Institutional Ownership Trends

Institutional Holdings Trend

DateHoldingsChange %
30 Sep, 225-
30 Jun, 225-37.50%
31 Mar, 228-

As of 30 Sep 22, 5 institutions are holding TC Biopharm's shares, representing an increase of 0.00% compared to the previous quarter.

Shares Outstanding Trend

DateShares OutstandingChange %
30 Sep, 22507,06312.34%
30 Jun, 22451,36461.74%
31 Mar, 22279,073-

TC Biopharm (TCBP) has 507.06K shares outstanding as of 30 Sep 22, up 12.34% compared to the previous quarter.

Institutional Ownership Trend

DateOwnership %Change %
30 Sep, 220.22%583.58%
30 Jun, 220.19%1359.16%
31 Mar, 220.12%-

As of 30 Sep 22, TC Biopharm is held by 0.22% institutional shareholders, representing a 583.58% growth compared to 30 Jun 22.

Institutional Increased Positions Trend

DateIncreased PositionsChange %
30 Sep, 223-40.00%
30 Jun, 225-37.50%
31 Mar, 228-

3 institutional shareholders have increased their position in TCBP stock as of 30 Sep 22 compared to 5 in the previous quarter (a -40.00% decrease).

Institutional Reduced Positions Trend

DateReduced PositionsChange %
30 Sep, 221-
30 Jun, 22--
31 Mar, 22--

1 institutional shareholders have reduced their position in TCBP stock as of 30 Sep 22 compared to - in the previous quarter (a 0.00% increase).

All Institutional Ownership Trend Data

DateHoldingsChange %Shares OutstandingChange %Ownership %Change %Increased PositionsChange %Reduced PositionsChange %
30 Sep, 225-507,06312.34%0.22%583.58%3-40.00%1-
30 Jun, 225-37.50%451,36461.74%0.19%1359.16%5-37.50%--
31 Mar, 228-279,073-0.12%-8---

TC Biopharm Insider Shareholders Trades

Open Market Insider Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Jan 11, 2023Randall Diana Elizabethdirector-P-PurchaseBuy70,000--70,000
Jan 11, 2023Randall Mark Edwarddirector-P-PurchaseBuy70,000$5.00$350.00K136,834
Jan 11, 2023Randall Mark Edwarddirector-P-PurchaseBuy70,000--70,000
Jan 11, 2023Randall Kenneth Edwarddirector-P-PurchaseBuy70,000$5.00$350.00K136,834
Jan 11, 2023Randall Kenneth Edwarddirector-P-PurchaseBuy70,000--70,000
Jan 11, 2023Randall Mark Edwarddirector-P-PurchaseBuy70,000$5.00$350.00K382,963
Jan 11, 2023Randall Mark Edwarddirector-P-PurchaseBuy70,000--70,000
Jan 11, 2023Randall Kenneth Edwarddirector-P-PurchaseBuy70,000$5.00$350.00K382,963
Jan 11, 2023Randall Kenneth Edwarddirector-P-PurchaseBuy70,000--70,000
Jan 11, 2023Renaissance Capital Partners Ltddirector-P-PurchaseBuy70,000$5.00$350.00K136,834
Jan 11, 2023Renaissance Capital Partners Ltddirector-P-PurchaseBuy70,000--70,000
Jul 14, 2022Randall Kenneth Edwarddirector P-PurchaseBuy20,803$1.15$23.92K100,418

Open Market Insider Buys

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Jan 11, 2023Randall Diana Elizabethdirector-P-PurchaseBuy70,000--70,000
Jan 11, 2023Randall Mark Edwarddirector-P-PurchaseBuy70,000$5.00$350.00K136,834
Jan 11, 2023Randall Mark Edwarddirector-P-PurchaseBuy70,000--70,000
Jan 11, 2023Randall Kenneth Edwarddirector-P-PurchaseBuy70,000$5.00$350.00K136,834
Jan 11, 2023Randall Kenneth Edwarddirector-P-PurchaseBuy70,000--70,000
Jan 11, 2023Randall Mark Edwarddirector-P-PurchaseBuy70,000$5.00$350.00K382,963
Jan 11, 2023Randall Mark Edwarddirector-P-PurchaseBuy70,000--70,000
Jan 11, 2023Randall Kenneth Edwarddirector-P-PurchaseBuy70,000$5.00$350.00K382,963
Jan 11, 2023Randall Kenneth Edwarddirector-P-PurchaseBuy70,000--70,000
Jan 11, 2023Renaissance Capital Partners Ltddirector-P-PurchaseBuy70,000$5.00$350.00K136,834
Jan 11, 2023Renaissance Capital Partners Ltddirector-P-PurchaseBuy70,000--70,000
Jul 14, 2022Randall Kenneth Edwarddirector P-PurchaseBuy20,803$1.15$23.92K100,418

Insider Sells

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
May 20, 2022Randall Kenneth Edward10 percent owner-Sell---79,615
Apr 27, 2022Renaissance Capital Partners Ltd10 percent owner-Sell---3,341,718
Apr 27, 2022Renaissance Capital Partners Ltd10 percent owner-Sell5,306,464$4.25$22.55M-

All Insider Owners Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Jan 11, 2023Randall Diana Elizabethdirector-P-PurchaseBuy70,000--70,000
Jan 11, 2023Randall Mark Edwarddirector-P-PurchaseBuy70,000$5.00$350.00K136,834
Jan 11, 2023Randall Mark Edwarddirector-P-PurchaseBuy70,000--70,000
Jan 11, 2023Randall Kenneth Edwarddirector-P-PurchaseBuy70,000$5.00$350.00K136,834
Jan 11, 2023Randall Kenneth Edwarddirector-P-PurchaseBuy70,000--70,000
Jan 11, 2023Randall Mark Edwarddirector-P-PurchaseBuy70,000$5.00$350.00K382,963
Jan 11, 2023Randall Mark Edwarddirector-P-PurchaseBuy70,000--70,000
Jan 11, 2023Randall Kenneth Edwarddirector-P-PurchaseBuy70,000$5.00$350.00K382,963
Jan 11, 2023Randall Kenneth Edwarddirector-P-PurchaseBuy70,000--70,000
Jan 11, 2023Renaissance Capital Partners Ltddirector-P-PurchaseBuy70,000$5.00$350.00K136,834
Jan 11, 2023Renaissance Capital Partners Ltddirector-P-PurchaseBuy70,000--70,000
Jul 14, 2022Randall Kenneth Edwarddirector P-PurchaseBuy20,803$1.15$23.92K100,418
May 23, 2022Randall Diana Elizabeth10 percent owner-Buy---3,421,333
May 23, 2022Randall Diana Elizabeth10 percent owner-Buy5,306,464$4.25$22.55M-
May 20, 2022Randall Kenneth Edward10 percent owner-Buy---3,341,718
May 20, 2022Randall Kenneth Edward10 percent owner-Sell---79,615
May 20, 2022Randall Kenneth Edward10 percent owner-Buy5,306,464$4.25$22.55M-
Apr 27, 2022Renaissance Capital Partners Ltd10 percent owner-Sell---3,341,718
Apr 27, 2022Renaissance Capital Partners Ltd10 percent owner-Sell5,306,464$4.25$22.55M-

The last insider sell of TC Biopharm's stock was made by Randall Kenneth Edward on May 20 2022, selling - shares at - per share (valued at -). The last insider buy of TCBP was made by Randall Diana Elizabeth on Jan 11 2023, buying 70,000 shares at - per share (worth -).

TC Biopharm Insider Ownership Trends

All Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q4 202211--
Q2 202211100.00%
Q1 2022-2-

11 total buy trades, and 0 total sell trades (buy/sell ratio of 0%) were made by TC Biopharm's insiders, as of Q4 2022.

Open Market Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q4 202211--
Q2 20221--
Q1 2022---

As of Q4 2022, Insider owners conducted 11 open market buy trades and 0 open market sell trades of TC Biopharm's stocks.

TC Biopharm Peer Ownership

TickerCompany
ZVSAZyVersa Therapeutics, Inc.
BDRXBiodexa Pharmaceuticals Plc
VIRIVirios Therapeutics, Inc.
ICUSeaStar Medical Holding Corporation
BWVOnconetix, Inc.
PXMDPaxMedica, Inc. Common Stock
PHIOPhio Pharmaceuticals Corp.
REVBRevelation Biosciences, Inc.
QNRXQuoin Pharmaceuticals, Ltd.
RNAZTransCode Therapeutics, Inc.
HILSTharimmune, Inc.
VRAXVirax Biolabs Group Limited
ALLRAllarity Therapeutics, Inc.
IMMXImmix Biopharma, Inc.
SONNSonnet BioTherapeutics Holdings, Inc.
UNCYUnicycive Therapeutics, Inc.
ZURAZura Bio Limited
PALIPalisade Bio, Inc.

TCBP Ownership FAQ

TC Biopharm is owned by institutional shareholders (0.22%), insiders (0.02%), and public (99.76%). The largest institutional shareholder of TC Biopharm is ARMISTICE CAPITAL, LLC (21.87% of total shares) and the top mutual fund owner is TRUST FOR PROFESSIONAL MANAGERS (0.00% of total shares).

TC Biopharm's major institutional shareholders are ARMISTICE CAPITAL, LLC, WELLS FARGO & COMPANY/MN, STEWARD FINANCIAL GROUP LLC, MORGAN STANLEY, and UBS GROUP AG. The top five shareholders own together 23.50% of the company's share outstanding.

As of Sep 2022, there are 5 institutional shareholders of TC Biopharm.

ARMISTICE CAPITAL, LLC owns 120.68K shares of TC Biopharm, representing 21.87% of the company's total shares outstanding, valued at $193.09M (as of Mar 2023).

As of Mar 2023, WELLS FARGO & COMPANY/MN holds 7K shares of TC Biopharm (TCBP), compromising 1.27% of the company, valued at $11.2M.

STEWARD FINANCIAL GROUP LLC is the third largest holder of TC Biopharm. The company owns 2K of the company's shares outstanding (worth $3K).